Change language dansk English suomi svenska

Generate Estimates Confirm Cancel Hide empty rows Show hidden rows DummyText

KLINIK FOR FODTERAPI ApS Estimate generation in progress, please wait... 0%

Quicksearch from your own companies XBRLDenmark Analyst: XBRLDenmark

Loading... Loading... Loading... Loading... Loading... Loading... Loading...

1000.0 Bankruptcy Risk  2018 2018/9 2019 2019/9 2020 2020/9 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Bankruptcy risk for industry   1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 0.8% 0.8%   Bankruptcy risk   21.2% 10.9% 11.4% 6.4% 10.8% 6.3% 15.8% 15.5%   Credit score (0-100)   5 24 21 36 22 36 12 13   Credit rating   B BB BB BBB BB BBB BB BB   Credit limit (kDKK)   0.0 0.0 0.0 0.0 0.0 0.0 -0.0 -0.0   How are these values calculated?   View the automatically generated explanation of bankruptcy risk 1000.0 Income statement (kDKK)  2018 2018/9 2019 2019/9 2020 2020/9 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   428 404 402 84 484 0 0 0   Gross profit   428 404 402 84.5 484 405 0.0 0.0   EBITDA   23.7 -0.3 10.1 -1.0 177 12.0 0.0 0.0   EBIT   10.5 -13.5 -3.2 -1.0 177 -0.2 0.0 0.0   Pre-tax profit (PTP)   8.3 -16.3 -3.2 -3.0 171.5 -7.1 0.0 0.0   Net earnings   4.4 -24.9 -3.2 -4.0 135.8 -7.1 0.0 0.0   Pre-tax profit without non-rec. items   8.3 -16.3 -3.2 -3.0 172 -7.1 0.0 0.0     See the entire income statement 1000.0 Balance sheet (kDKK)  2018 2018/9 2019 2019/9 2020 2020/9 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Tangible assets total   34.4 121 212 390 390 426 0.0 0.0   Shareholders equity total   103 78.6 64.2 94.9 231 189 -7.1 -7.1   Interest-bearing liabilities   0.0 0.0 65.7 75.1 66.3 171 7.1 7.1   Balance sheet total (assets)   77.7 148 218 404 410 446 0.0 0.0   Net Debt   -2.9 -9.0 61.3 71.0 58.7 171 7.1 7.1     See the entire balance sheet 1000.0 Volume  2018 2018/9 2019 2019/9 2020 2020/9 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   428 404 402 84 484 0 0 0   Net sales growth   3.2% -5.7% -0.3% -79.0% 472.8% -100.0% 0.0% 0.0%   Gross profit   428 404 402 84.5 484 405 0.0 0.0   Gross profit growth   3.2% -5.7% -0.3% -79.0% 472.8% -16.3% -100.0% 0.0%   Employees   0 0 0 0 0 0 0 0   Employee growth %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Employee expenses   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   78 148 218 404 410 446 0 0   Balance sheet change%   -11.7% 89.8% 47.5% 85.6% 1.6% 8.7% -100.0% 0.0%   Added value   23.7 -0.3 10.1 -1.0 176.5 12.0 0.0 0.0   Added value %   5.5%   2.5% -1.1% 36.5% 0.0% 0.0% 0.0%   Investments   -27 74 78 178 0 24 -426 0   Net sales trend   2.0 -1.0 -2.0 -3.0 1.0 -1.0 0.0 0.0   EBIT trend   2.0 -1.0 -2.0 -3.0 1.0 -1.0 0.0 0.0   1000.0 Profitability  2018 2018/9 2019 2019/9 2020 2020/9 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A EBITDA %   5.5% -0.1% 2.5% -1.1% 36.5% 0.0% 0.0% 0.0%   EBIT %   2.4% -3.4% -0.8% -1.1% 36.5% 0.0% 0.0% 0.0%   EBIT to gross profit (%)   2.4% -3.4% -0.8% -1.1% 36.5% -0.0% 0.0% 0.0%   Net Earnings %   1.0% -6.2% -0.8% -4.7% 28.1% 0.0% 0.0% 0.0%   Profit before depreciation and extraordinary items %   4.1% -2.9% 2.5% -4.7% 28.1% 0.0% 0.0% 0.0%   Pre tax profit less extraordinaries %   1.9% -4.0% -0.8% -3.6% 35.4% 0.0% 0.0% 0.0%   ROA %   12.6% -12.0% -1.7% -0.3% 43.4% -0.0% 0.0% 0.0%   ROI %   9.5% -14.9% -3.1% -0.6% 75.6% -0.1% 0.0% 0.0%   ROE %   4.0% -27.3% -4.5% -5.0% 83.4% -3.4% 0.0% 0.0%   1000.0 Solidity  2018 2018/9 2019 2019/9 2020 2020/9 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Equity ratio %   80.1% 53.3% 29.5% 23.5% 56.2% 42.3% -100.0% -100.0%   Relative indebtedness %   -6.0% 17.1% 38.1% 365.8% 37.1% 0.0% 0.0% 0.0%   Relative net indebtedness %   -6.7% 14.9% 37.0% 360.9% 35.5% 0.0% 0.0% 0.0%   Net int. bear. debt to EBITDA, %   -12.0% 3,123.7% 609.2% -7,398.4% 33.3% 1,431.3% 0.0% 0.0%   Gearing %   0.0% 0.0% 102.5% 79.1% 28.7% 90.9% -100.0% -100.0%   Net interest   0 0 0 0 0 0 0 0   Financing costs %   0.0% 0.0% 0.0% 3.0% 7.1% 5.8% 0.0% 0.0%   1000.0 Liquidity  2018 2018/9 2019 2019/9 2020 2020/9 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Quick Ratio   -1.7 0.4 0.0 0.0 0.1 0.1 0.0 0.0   Current Ratio   -1.7 0.4 0.0 0.0 0.1 0.1 0.0 0.0   Cash and cash equivalent   2.9 9.0 4.4 4.1 7.6 0.0 0.0 0.0   1000.0 Capital use efficiency  2018 2018/9 2019 2019/9 2020 2020/9 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Trade debtors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Trade creditors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Current assets / Net sales %   10.1% 6.5% 1.3% 16.5% 4.2% 0.0% 0.0% 0.0%   Net working capital   69.0 -42.7 -148.1 -295.1 -159.3 -237.9 -3.5 -3.5   Net working capital %   16.1% -10.6% -36.8% -349.3% -32.9% 0.0% 0.0% 0.0%   1000.0 Employee efficiency  2018 2018/9 2019 2019/9 2020 2020/9 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales / employee   0 0 0 0 0 0 0 0   Added value / employee   0 0 0 0 0 0 0 0   Employee expenses / employee   0 0 0 0 0 0 0 0   EBITDA / employee   0 0 0 0 0 0 0 0   EBIT / employee   0 0 0 0 0 0 0 0   Net earnings / employee   0 0 0 0 0 0 0 0